Replimune Group (NASDAQ:REPL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $17.00 price objective on the stock.

Other analysts have also recently issued reports about the company. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. JPMorgan Chase & Co. raised their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $17.00.

Replimune Group Stock Performance

NASDAQ:REPL opened at $14.93 on Friday. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average price of $11.51 and a 200 day moving average price of $9.67.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, analysts forecast that Replimune Group will post -3.02 EPS for the current year.

Insider Activity

In related news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its position in Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the last quarter. Point72 DIFC Ltd acquired a new position in Replimune Group in the second quarter worth approximately $57,000. Arizona State Retirement System acquired a new position in Replimune Group in the second quarter worth approximately $108,000. Quest Partners LLC grew its position in Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new position in Replimune Group in the third quarter worth approximately $133,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.